Solventum (NYSE:SOLV) Raised to “Strong-Buy” at Zacks Research

Solventum (NYSE:SOLV – Get Free Report) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Thursday, Zacks reports.

A number of other research firms have also recently issued reports on SOLV. Piper Sandler reiterated an “overweight” rating and set a $110.00 target price (up from $105.00) on shares of Solventum in a report on Friday, November 6th. KeyCorp boosted their price target on Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Solventum in a research report on Thursday, October 8th. Canadian Imperial Bank of Commerce set a $35.00 price objective on Solventum in a report on Wednesday, October 28th. Finally, Wedbush lifted their target price on Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $90.27.

Get Our Latest Analysis on Solventum

Solventum Stock Up 0.0%

Shares of Solventum stock traded up $0.04 on Thursday, hitting $88.85. The company had a trading volume of 917,954 shares, compared to its average volume of 1,291,136. The firm has a market capitalization of $15.08 billion, a P/E ratio of 99.83, a P/E/G ratio of 1.26 and a beta of 0.69. Solventum has a twelve month low of $62.38 and a twelve month high of $94.16. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.03 and a quick ratio of 0.72. The stock has a 50-day moving average of $87.53 and a 200-day moving average of $78.95.

Solventum (NYSE:SOLV – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.11. The business had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.93 billion. Solventum had a net margin of 1.91% and a return on equity of 25.03%. The firm’s quarterly revenue was down 7.0% on a year-over-year basis. During the same period last year, the business posted $1.50 earnings per share. Research analysts predict that Solventum will post 7.26 earnings per share for the current year.

Institutional Investors Weigh In On Solventum

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SOLV. Empowered Funds LLC bought a new stake in Solventum during the 3rd quarter worth about $881,000. Steward Partners Investment Advisory LLC grew its holdings in shares of Solventum by 27.4% in the 3rd quarter. Steward Partners Investment Advisory LLC now owns 8,067 shares of the company’s stock valued at $711,000 after acquiring an additional 1,737 shares in the last quarter. Essex Financial Services Inc. acquired a new stake in shares of Solventum in the third quarter valued at about $253,000. N.F.U. MUTUAL UNIT MANAGERS Ltd bought a new stake in Solventum during the third quarter worth about $654,000. Finally, First Trust Advisors LP raised its holdings in Solventum by 20.9% during the third quarter. First Trust Advisors LP now owns 492,343 shares of the company’s stock worth $43,400,000 after acquiring an additional 85,127 shares in the last quarter.

Solventum Company Profile

(Get Free Report)

Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M’s healthcare business and became an independent public company in April 2024. The company’s offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.

Further Reading

Analyst Recommendations for Solventum (NYSE:SOLV)

Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.